HOME >> BIOLOGY >> NEWS
Pacific Northwest chemist wins national award for studies of biological systems

Richard D. Smith of Richland, Wash., will be honored March 25 by the world's largest scientific society for his achievements in developing ever-finer tools with which to study and understand biological processes. He will receive the 2003 Award in Analytical Chemistry from the American Chemical Society at its national meeting in New Orleans.

"We're aiming to characterize as completely as we can these incredibly complex biological systems, to see all of them in all their detail and glory," said Smith, a chemist and Battelle Fellow at the Pacific Northwest National Laboratory.

While biological systems being studied today are on the order of learning how the body makes a certain antibody to fight infection, for example, the ultimate system is the human body itself.

"We want to get to where we can picture it in so much detail that, using computers, we can predict the effect of a complex perturbation -- a drug's side effects, exposure to a virus, whatever," said Smith. "We're about 2 percent of the way there, but we'll quickly get up to 10 [percent], I think."

Thus Smith develops increasingly selective methods to separate biological mixtures of proteins, carbohydrates, hormones and other compounds. His separations are based on what is called capillary liquid chromatography, tiny tubes packed with chemically sensitive "beads" that tease apart mixtures according to size, electrical charge and other molecular properties.

Once separated, Smith and his research team analyze the various components with a powerful mass spectrometer. "We developed this technique to identify the molecules and do measurements to tell how much we have," he said. "As our approach gets better and better, we can also narrow down where molecules are coming from, where they act and with what [other molecules]."

When asked how he became interested in science, particularly chemistry, Smith said, "For some reason I decided by age 5 that I wanted to be a chemis
'"/>

Contact: Allison Byrum
a_byrum@acs.org
202-872-4400
American Chemical Society
4-Mar-2003


Page: 1 2

Related biology news :

1. Pacific Northwest team unveils largest virus proteome to date
2. New hydrothermal vents discovered as South Pacific Odyssey research begins
3. Pacific Northwest National Laboratory gets $10 million from NIH to build virtual lung
4. Anti-plume found off Pacific Coast
5. Institute for Systems Biology, Pacific Northwest National Laboratory announce collaboration
6. Pacific leatherback turtle could go extinct in 10 years
7. Pacific Northwest National Lab unveils most complete human blood-plasma proteome map to date
8. Fish, FRAMES and sticky chemicals net technology award for Pacific Northwest National Laboratory
9. DuPont to locate Asia Pacific R&D center in Shanghai
10. LabNotes -- Research highlights from Pacific Northwest National Laboratory
11. Collapse of seals, sea lions & sea otters in North Pacific triggered by overfishing of great whales

Post Your Comments:
(Date:4/27/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market, announces that its Wocket® ... first week of May, 2015 and will be fulfilling ... Gino Pereira , Chief Executive Officer ... as Wocket® enters the consumer market. We would like ...
(Date:4/20/2015)... PASADENA, Calif. , April 20, 2015 ... San Gabriel Valley to implant a new miniaturized, wireless ... HF System is the first and only FDA-approved heart ... reduce hospital admissions when used by physicians to manage ... a sensor that is implanted in the pulmonary artery ...
(Date:4/14/2015)... 2015  HYPR Corp. today announced it has ... Alliance tm , an industry consortium transforming online ... share technology and collaborate to deliver open specifications ... secure and private, and easier to use. ... protects sensitive user information and eliminates the dependency ...
Breaking Biology News(10 mins):Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3
(Date:5/21/2015)... , May 21, 2015  The EveryLife Foundation ... (R-UT) and Amy Klobuchar (D-MN) ... Accelerating Cures & Treatments, or OPEN ACT. ... patient advocacy organizations, this bipartisan legislation promises to ... medicines to rare disease patients by incentivizing drug ...
(Date:5/21/2015)... W. R. Grace & Co. (NYSE: ... Germany has received good manufacturing practice (GMP) certification ... Pharmaceutical Excipient Council (IPEC) Foundation. , ... FP brand of pharmaceutical grade excipient silica gels ... Bay, Maryland (USA) and Sorocaba, Brazil locations. The ...
(Date:5/21/2015)... , May 21, 2015  CytRx Corporation (NASDAQ: ... company specializing in oncology, today announced positive updated ... with aldoxorubicin for the treatment of unresectable glioblastoma ...  The open-label, multisite trial is designed to investigate ... patients whose tumors have progressed following prior treatment ...
(Date:5/21/2015)... May 20, 2015 Research and Markets ... of the "2015 Global Survey on Flow ... The primary goal of this research ... instruments and reagents. Key information the survey seeks ... of flow cytometers, predominantly used applications for flow ...
Breaking Biology Technology:Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Global Survey on Flow Cytometry Adoption Trends 2015 2
Cached News: